NanoSphere Health Sciences Announces Patent-Pending Status for Nanoparticle Encapsulation of NSAIDs

DENVER, Jan. 13, 2015 /PRNewswire/ -- NanoSphere Health Sciences, LLC, innovative developers of the industry-first, patent-pending NanoSphere™ delivery system, announced today that the U.S. Patent and Trademark office issued "Patent Pending" status for its new NSAID NanoSphere technology platform.

NanoSphere Health's NSAIDs are the first to encapsulate prescription and over-the-counter (OTC) NSAIDs (non-steroidal anti-inflammatory drugs such as Ibuprofen, Aspirin, Naproxen, etc.) as a method to treat and prevent inflammatory disorders and global inflammation and pain. The use of the NanoSphere delivery technology eliminates and alleviates many of the severe side effects NSAIDs can have, such as stomach irritation, stomach bleeding and GI bleeding, among others. At the same time, it increases the therapeutic activity of NSAIDs for safe, long-term and more effective therapy.  

NanoSphere NSAIDs are uniquely designed to be administered intraorally, intranasally and transdermally. The convenient liquid nanogels bypass the GI tract avoiding gastrointestinal irritation. When taken perorally, NanoSphere NSAIDs' structure of purified essential phospholipids maintains the protective GI tract mucosa barrier from damage by NSAIDs. The NanoSphere NSAIDs are then efficiently transported into the circulatory system for greater therapeutic activity in safely treating inflammatory conditions and relieving pain.

"We are excited to announce that NanoSphere's NSAID technology platform has achieved a 'Patent Pending' status, protecting the intellectual property of our NanoSphere delivery system within NSAIDs," said Dr. Richard Kaufman, Chief Science Officer at NanoSphere Health Sciences. "Our disruptive NanoSphere delivery biotechnology introduces a significant advancement in the therapeutic potential and safety of OTC and prescription NSAIDs along with a tremendous growth potential."

NSAIDs cause a range of gastrointestinal problems from mild upset stomach to serious conditions such as stomach bleeding, ulcers and kidney damage, factors which often limit their use. Among patients using NSAIDs, 30-40% have some degree of GI intolerance. NSAIDs physically damage the protective GI mucosa surface and promote bleeding. Furthermore, NSAIDs are fat-soluble drugs with low solubility and dissolution in water. This makes OTC and prescription NSAID pills hard to absorb and contributes to their causing GI problems.

"The problems with current NSAID therapy are glaringly apparent," says Terry Grossman M.D., Medical Director at NanoSphere Health Sciences. "NSAIDs have low bioavailability and limited delivery into inflamed areas. They produce adverse effects, compounded with the fact that nearly half the population has difficulties swallowing currently sold NSAID pills and capsules."

The company's patent-pending phospholipid nanoparticle encapsulation of NSAIDs technology provides the following potential benefits:

• Higher Concentration of NSAIDs
• Increased Bioavailability of NSAIDs (2-fold to 10-fold)
• Decreased Dosage of NSAIDS (2-fold to 10-fold)
• Enables Safe, Long-Term Use and More Efficacious NSAID Therapy and Treatment
• Reduced Risk of Gastrointestinal Problems
• Transport into and Targeting of Specific Body Sites
• Delivery into the Central Nervous System
• Enhanced Therapeutic Value
• Ideal for Long-Term and Daily Use

NanoSphere Health expects availability of commercial licensing by the second quarter of 2015, after clinical trials have been completed.

About NanoSphere Health Sciences, LLC
With its headquarters in Denver, Colorado, NanoSphere Health Sciences is a biotechnology firm specializing in the creation of NanoSphere™ delivery systems for the supplement, nutraceutical, OTC and pharmaceutical industries.
For more information, visit www.nanospherehealth.com.

SOURCE NanoSphere Health Sciences, LLC

Related Links

http://www.nanospherehealth.com